Physician profile
Egbert Miranda
NPI 1093785230
$3,055.07
in general payments reported to CMS, 2019-2025
29 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $313 · 2021: $202 · 2022: $238 · 2023: $395 · 2024: $507 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749 · Gift: $59.40 · Entertainment: $14.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.90 |
| Gift | $59.40 |
| Entertainment | $14.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $471.69 | 2023-2025 | |
| Lilly USA, LLC | $361.99 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Mannkind Corporation | $335.54 | 2023-2025 | Afrezza |
| Abbott Laboratories | $315.16 | 2019-2025 | Freestyle Libre |
| Amgen INC. | $253.02 | 2019-2025 | Repatha, Tepezza, Repatha |
| Novo Nordisk INC | $197.19 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $191.51 | 2022-2025 | Isturisa |
| Astrazeneca Pharmaceuticals Lp | $128.88 | 2019 | |
| Insulet Corporation | $120.51 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $109.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $71.14 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $57.35 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $48.49 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $42.70 | 2025 | Twiist |
| Eusa Pharma (US) LLC | $41.29 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $38.62 | 2024-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.71 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $29.63 | 2025 | Yorvipath |
| Radius Health, INC. | $28.76 | 2024 | Tymlos |
| Medtronic, INC. | $27.80 | 2025 | Minimed 780g |
| Sandoz INC. | $24.57 | 2025 | |
| Corcept Therapeutics | $22.28 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.77 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.87 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $15.43 | 2021 | |
| Optos, INC. | $14.20 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Ibsa Pharma INC. | $12.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Grt US Holding, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Egbert Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.